Business
Reuters Features Medical Marijuana, Inc.'s Major Investment Company AXIM Biotech In Article Citing Company's Development Of Marijuana-Based Painkiller To Combat Opioid Crisis
Reuters Features Medical Marijuana, Inc.'s Major Investment Company AXIM Biotech In Article Citing Company's Development Of Marijuana-Based Painkiller To Combat Opioid Crisis.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n\n\nReuters Features Medical Marijuana, Inc.'s Major Investment Company AXIM Biotech In Article Citing Company's Development Of Marijuana-Based Painkiller To Combat Opioid Crisis\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nReuters Features Medical Marijuana, Inc.'s Major Investment Company AXIM Biotech In Article Citing Company's Development Of Marijuana-Based Painkiller To Combat Opioid Crisis\nPR Newswire\nNEW YORK, June 27, 2017\n\n\n\nNEW YORK, June 27, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, was featured in a Reuters article focused on companies that are developing marijuana-based painkillers to help combat America's opioid crisis.  \n\nThe June 23, 2017 article \"High hopes ride on marijuana painkillers amid opioid crisis,\" which also ran in Fortune, Scientific American, CNBC, Business Insider, and the Daily Mail, features AXIM Biotech for the preclinical studies it is conducting on a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment, for which it expects to submit an FDA application to start a trial on opioid-dependent patients this year.  \n\nThe article states: \"The companies are targeting more than 100 million Americans who suffer from chronic pain, and are dependent on opioid painkillers such as Vicodin, or addicted to street opiates including heroin.\"  \n\n\"We are grateful that Reuters is covering companies like AXIM that are developing alternatives for the roughly 2.5 million Americans addicted to opioids,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"The future of pain management, a $100 billion market, may be a high dose of cannabis and a low dose of opioids. Already, we are seeing the incidence of prescription drug overdose death 25% lower in states where medical cannabis ...